FOLH1 and metastatic malignant neoplasm in the lymph nodes: Potentially, this higher sensitivity for lymph-node metastases is explained by the inclusion of more patients with high-risk disease (100.0% vs. our 63.3%), bearing higher PSMA expressing metastases [9].